Regeneron halts trial of COVID-19 antibody drug in sickest hospitalized patients

The Hill: Regeneron Pharmaceuticals said Friday it has paused a clinical study of its antibody drug to treat some of the sickest COVID-19 patients because of a potential safety concern.

The recommendation from an independent monitoring board marks the second time a clinical trial of an experimental coronavirus antibody drug has been paused because of safety issues.

Read article

Share